| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cancer Survivors | 81 | 2024 | 650 | 11.190 |
Why?
|
| Radiometry | 24 | 2022 | 980 | 3.430 |
Why?
|
| Phantoms, Imaging | 33 | 2023 | 1271 | 3.330 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 44 | 2023 | 2370 | 2.900 |
Why?
|
| Neutrons | 14 | 2019 | 117 | 2.900 |
Why?
|
| Photons | 17 | 2022 | 507 | 2.410 |
Why?
|
| Radiation Dosage | 17 | 2023 | 1014 | 2.130 |
Why?
|
| Neoplasms | 55 | 2024 | 15193 | 1.910 |
Why?
|
| Radiotherapy Dosage | 41 | 2023 | 3842 | 1.770 |
Why?
|
| Printing, Three-Dimensional | 4 | 2020 | 129 | 1.750 |
Why?
|
| Deglutition Disorders | 4 | 2021 | 447 | 1.580 |
Why?
|
| Heart Diseases | 8 | 2023 | 732 | 1.570 |
Why?
|
| Neoplasms, Radiation-Induced | 15 | 2023 | 388 | 1.550 |
Why?
|
| Radiotherapy, Intensity-Modulated | 22 | 2023 | 2104 | 1.530 |
Why?
|
| Neoplasms, Second Primary | 18 | 2023 | 1350 | 1.460 |
Why?
|
| Survivors | 27 | 2024 | 1031 | 1.380 |
Why?
|
| Craniospinal Irradiation | 6 | 2023 | 128 | 1.310 |
Why?
|
| Proton Therapy | 11 | 2016 | 1577 | 1.230 |
Why?
|
| Child | 86 | 2024 | 29154 | 1.180 |
Why?
|
| Radiotherapy | 11 | 2020 | 1824 | 1.160 |
Why?
|
| Radiation Injuries | 8 | 2023 | 1411 | 1.110 |
Why?
|
| Radiation Oncology | 6 | 2023 | 529 | 1.090 |
Why?
|
| Wilms Tumor | 5 | 2023 | 292 | 1.070 |
Why?
|
| Esophagoscopy | 2 | 2018 | 291 | 1.060 |
Why?
|
| Organs at Risk | 10 | 2023 | 514 | 1.030 |
Why?
|
| Medulloblastoma | 7 | 2023 | 540 | 0.960 |
Why?
|
| Particle Accelerators | 9 | 2018 | 352 | 0.930 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2022 | 20 | 0.860 |
Why?
|
| Head and Neck Neoplasms | 8 | 2021 | 3976 | 0.840 |
Why?
|
| Cerebellar Neoplasms | 5 | 2023 | 434 | 0.840 |
Why?
|
| Radiation Exposure | 2 | 2021 | 73 | 0.830 |
Why?
|
| Algorithms | 17 | 2023 | 3890 | 0.780 |
Why?
|
| Adolescent | 54 | 2023 | 31252 | 0.770 |
Why?
|
| Uncertainty | 5 | 2020 | 320 | 0.750 |
Why?
|
| Humans | 162 | 2024 | 261506 | 0.750 |
Why?
|
| Adult | 81 | 2024 | 77950 | 0.710 |
Why?
|
| Radiobiology | 1 | 2020 | 56 | 0.710 |
Why?
|
| Child, Preschool | 34 | 2023 | 16273 | 0.710 |
Why?
|
| Epidemiologic Studies | 1 | 2019 | 60 | 0.690 |
Why?
|
| Risk Factors | 45 | 2024 | 17523 | 0.670 |
Why?
|
| Scattering, Radiation | 6 | 2015 | 316 | 0.650 |
Why?
|
| Dilatation | 1 | 2018 | 83 | 0.620 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2023 | 7551 | 0.620 |
Why?
|
| Esophageal Stenosis | 1 | 2018 | 83 | 0.620 |
Why?
|
| Breast Neoplasms | 20 | 2024 | 15694 | 0.610 |
Why?
|
| Young Adult | 43 | 2024 | 21445 | 0.610 |
Why?
|
| Scalp | 1 | 2019 | 156 | 0.610 |
Why?
|
| Male | 85 | 2024 | 123000 | 0.600 |
Why?
|
| Female | 95 | 2024 | 141928 | 0.590 |
Why?
|
| Radiotherapy, Conformal | 5 | 2023 | 902 | 0.570 |
Why?
|
| Siblings | 10 | 2023 | 285 | 0.550 |
Why?
|
| Kidney Neoplasms | 5 | 2023 | 3022 | 0.540 |
Why?
|
| Chronic Disease | 10 | 2024 | 1819 | 0.540 |
Why?
|
| Mastectomy | 4 | 2019 | 1534 | 0.540 |
Why?
|
| Risk Assessment | 16 | 2021 | 6869 | 0.530 |
Why?
|
| X-Rays | 2 | 2020 | 146 | 0.520 |
Why?
|
| Heart Failure | 4 | 2024 | 2516 | 0.520 |
Why?
|
| Retrospective Studies | 43 | 2023 | 37905 | 0.520 |
Why?
|
| Dose-Response Relationship, Radiation | 9 | 2023 | 726 | 0.490 |
Why?
|
| Quality of Life | 13 | 2024 | 4532 | 0.490 |
Why?
|
| Stroke | 4 | 2024 | 1144 | 0.480 |
Why?
|
| Spectrum Analysis | 1 | 2014 | 139 | 0.470 |
Why?
|
| Hodgkin Disease | 7 | 2022 | 1429 | 0.450 |
Why?
|
| Neuroblastoma | 5 | 2023 | 686 | 0.450 |
Why?
|
| Cranial Irradiation | 3 | 2019 | 315 | 0.440 |
Why?
|
| Primary Ovarian Insufficiency | 3 | 2023 | 72 | 0.440 |
Why?
|
| Infant | 19 | 2023 | 13310 | 0.440 |
Why?
|
| Stress, Psychological | 4 | 2020 | 1000 | 0.430 |
Why?
|
| Middle Aged | 53 | 2024 | 86204 | 0.410 |
Why?
|
| Head | 4 | 2021 | 249 | 0.400 |
Why?
|
| Cohort Studies | 21 | 2023 | 9244 | 0.400 |
Why?
|
| Skin Neoplasms | 4 | 2024 | 4654 | 0.390 |
Why?
|
| Infant, Newborn | 15 | 2023 | 8223 | 0.390 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2023 | 502 | 0.390 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 4320 | 0.380 |
Why?
|
| Software | 5 | 2015 | 1321 | 0.360 |
Why?
|
| Incidence | 16 | 2022 | 5673 | 0.350 |
Why?
|
| Exercise Tolerance | 2 | 2020 | 107 | 0.350 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 1054 | 0.340 |
Why?
|
| Neurocognitive Disorders | 2 | 2021 | 69 | 0.340 |
Why?
|
| Renal Insufficiency | 2 | 2023 | 321 | 0.340 |
Why?
|
| Canada | 8 | 2023 | 429 | 0.340 |
Why?
|
| Models, Biological | 4 | 2013 | 3254 | 0.330 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2024 | 272 | 0.330 |
Why?
|
| Radiation Protection | 3 | 2011 | 205 | 0.330 |
Why?
|
| Anthracyclines | 5 | 2023 | 331 | 0.320 |
Why?
|
| Sleep Wake Disorders | 2 | 2024 | 348 | 0.320 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2019 | 5437 | 0.320 |
Why?
|
| Research Report | 2 | 2019 | 144 | 0.310 |
Why?
|
| Neck | 2 | 2021 | 383 | 0.310 |
Why?
|
| Optically Stimulated Luminescence Dosimetry | 2 | 2019 | 16 | 0.300 |
Why?
|
| Models, Theoretical | 3 | 2020 | 785 | 0.300 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 3578 | 0.290 |
Why?
|
| Thermoluminescent Dosimetry | 2 | 2019 | 77 | 0.270 |
Why?
|
| Prostatic Neoplasms | 7 | 2015 | 5767 | 0.270 |
Why?
|
| Heart | 5 | 2020 | 1223 | 0.270 |
Why?
|
| Quality Assurance, Health Care | 2 | 2021 | 585 | 0.270 |
Why?
|
| Health Status | 4 | 2023 | 590 | 0.270 |
Why?
|
| United States | 16 | 2023 | 15433 | 0.260 |
Why?
|
| Cardiomyopathies | 2 | 2021 | 610 | 0.250 |
Why?
|
| Monte Carlo Method | 9 | 2021 | 671 | 0.250 |
Why?
|
| Genome-Wide Association Study | 7 | 2024 | 2265 | 0.250 |
Why?
|
| Calibration | 3 | 2020 | 337 | 0.240 |
Why?
|
| Surveys and Questionnaires | 7 | 2021 | 5687 | 0.240 |
Why?
|
| Aged | 23 | 2022 | 70117 | 0.240 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 2796 | 0.240 |
Why?
|
| Feasibility Studies | 2 | 2021 | 2292 | 0.240 |
Why?
|
| Prospective Studies | 9 | 2023 | 12873 | 0.240 |
Why?
|
| Polyketides | 1 | 2023 | 2 | 0.240 |
Why?
|
| Esophagus | 3 | 2018 | 553 | 0.240 |
Why?
|
| Computer Simulation | 6 | 2020 | 1529 | 0.230 |
Why?
|
| Prediabetic State | 1 | 2023 | 57 | 0.230 |
Why?
|
| Morbidity | 5 | 2023 | 397 | 0.230 |
Why?
|
| Hypothyroidism | 2 | 2021 | 204 | 0.220 |
Why?
|
| North America | 5 | 2023 | 314 | 0.210 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 2195 | 0.210 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2016 | 295 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2023 | 6915 | 0.200 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 1225 | 0.200 |
Why?
|
| Sexism | 1 | 2021 | 51 | 0.200 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2019 | 1648 | 0.200 |
Why?
|
| Water | 2 | 2021 | 361 | 0.200 |
Why?
|
| Tinnitus | 1 | 2021 | 38 | 0.200 |
Why?
|
| Self Report | 3 | 2020 | 756 | 0.200 |
Why?
|
| Cognitive Dysfunction | 2 | 2023 | 333 | 0.190 |
Why?
|
| Neuromuscular Diseases | 1 | 2021 | 63 | 0.190 |
Why?
|
| Glioma | 2 | 2024 | 1963 | 0.190 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 202 | 0.190 |
Why?
|
| Positron-Emission Tomography | 4 | 2019 | 2173 | 0.190 |
Why?
|
| Longitudinal Studies | 6 | 2021 | 1945 | 0.180 |
Why?
|
| Postal Service | 1 | 2020 | 17 | 0.180 |
Why?
|
| Gallbladder Diseases | 1 | 2020 | 43 | 0.180 |
Why?
|
| Physicians, Women | 1 | 2021 | 105 | 0.180 |
Why?
|
| Pituitary Diseases | 1 | 2019 | 18 | 0.180 |
Why?
|
| Leydig Cells | 1 | 2019 | 39 | 0.180 |
Why?
|
| Overweight | 1 | 2023 | 484 | 0.180 |
Why?
|
| Congresses as Topic | 1 | 2021 | 298 | 0.180 |
Why?
|
| Equipment and Supplies | 1 | 2019 | 48 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 171 | 0.180 |
Why?
|
| Automation | 4 | 2022 | 151 | 0.180 |
Why?
|
| Peer Review | 1 | 2020 | 80 | 0.180 |
Why?
|
| Risk Adjustment | 1 | 2020 | 83 | 0.180 |
Why?
|
| Life Expectancy | 1 | 2020 | 129 | 0.180 |
Why?
|
| Healthcare Failure Mode and Effect Analysis | 1 | 2019 | 8 | 0.170 |
Why?
|
| Vulvar Neoplasms | 1 | 2021 | 236 | 0.170 |
Why?
|
| Cholecystectomy | 1 | 2020 | 107 | 0.170 |
Why?
|
| Specialties, Surgical | 1 | 2021 | 137 | 0.170 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2019 | 13 | 0.170 |
Why?
|
| Self-Examination | 1 | 2019 | 12 | 0.170 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2019 | 33 | 0.170 |
Why?
|
| Receptors, Presynaptic | 1 | 2019 | 27 | 0.170 |
Why?
|
| Rectal Diseases | 1 | 2019 | 55 | 0.170 |
Why?
|
| Breast | 4 | 2023 | 1344 | 0.170 |
Why?
|
| Sarcoma, Ewing | 1 | 2023 | 406 | 0.170 |
Why?
|
| Risk | 7 | 2021 | 1972 | 0.170 |
Why?
|
| Hypothalamic Diseases | 1 | 2019 | 66 | 0.170 |
Why?
|
| Spine | 2 | 2022 | 293 | 0.170 |
Why?
|
| Antineoplastic Agents | 6 | 2022 | 14289 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 1 | 2020 | 144 | 0.170 |
Why?
|
| Age Factors | 8 | 2023 | 5377 | 0.170 |
Why?
|
| Troponin T | 1 | 2020 | 261 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 189 | 0.170 |
Why?
|
| Menopause, Premature | 1 | 2018 | 17 | 0.170 |
Why?
|
| Artifacts | 4 | 2018 | 532 | 0.170 |
Why?
|
| Metals | 2 | 2016 | 155 | 0.170 |
Why?
|
| Prevalence | 6 | 2021 | 3260 | 0.160 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2020 | 1833 | 0.160 |
Why?
|
| Abdominal Neoplasms | 1 | 2020 | 231 | 0.160 |
Why?
|
| Follow-Up Studies | 10 | 2023 | 14889 | 0.160 |
Why?
|
| Sex Factors | 3 | 2021 | 2139 | 0.160 |
Why?
|
| Multiple Organ Failure | 1 | 2019 | 177 | 0.160 |
Why?
|
| Social Adjustment | 1 | 2018 | 114 | 0.160 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 343 | 0.160 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 116 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2019 | 699 | 0.150 |
Why?
|
| Frailty | 1 | 2019 | 113 | 0.150 |
Why?
|
| Societies, Medical | 2 | 2021 | 1335 | 0.150 |
Why?
|
| Relative Biological Effectiveness | 3 | 2016 | 219 | 0.150 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 6009 | 0.150 |
Why?
|
| Models, Statistical | 5 | 2019 | 1171 | 0.150 |
Why?
|
| Splenectomy | 1 | 2018 | 158 | 0.150 |
Why?
|
| Coronary Artery Disease | 2 | 2024 | 1011 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2019 | 191 | 0.150 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2018 | 108 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 306 | 0.140 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 4988 | 0.140 |
Why?
|
| Pancreas | 1 | 2020 | 718 | 0.140 |
Why?
|
| Proxy | 1 | 2016 | 23 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2018 | 5539 | 0.140 |
Why?
|
| Adolescent Behavior | 1 | 2018 | 230 | 0.140 |
Why?
|
| Physics | 1 | 2016 | 44 | 0.140 |
Why?
|
| Heavy Ion Radiotherapy | 1 | 2016 | 25 | 0.140 |
Why?
|
| Spleen | 1 | 2018 | 676 | 0.140 |
Why?
|
| Lung Neoplasms | 4 | 2021 | 11538 | 0.130 |
Why?
|
| Myeloproliferative Disorders | 1 | 2023 | 767 | 0.130 |
Why?
|
| Postoperative Period | 1 | 2017 | 665 | 0.130 |
Why?
|
| Dental Amalgam | 1 | 2015 | 8 | 0.130 |
Why?
|
| Emotions | 1 | 2019 | 562 | 0.130 |
Why?
|
| Esophagitis | 1 | 2016 | 202 | 0.130 |
Why?
|
| Hormone Replacement Therapy | 1 | 2017 | 205 | 0.130 |
Why?
|
| Electrons | 1 | 2016 | 168 | 0.130 |
Why?
|
| Health Behavior | 1 | 2019 | 603 | 0.130 |
Why?
|
| Early Detection of Cancer | 2 | 2022 | 1258 | 0.130 |
Why?
|
| Body Burden | 2 | 2005 | 65 | 0.130 |
Why?
|
| Hip Prosthesis | 1 | 2015 | 30 | 0.130 |
Why?
|
| Synapses | 1 | 2019 | 509 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 882 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2018 | 588 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 787 | 0.130 |
Why?
|
| Peptide Fragments | 1 | 2020 | 1271 | 0.130 |
Why?
|
| Depression | 3 | 2020 | 1715 | 0.130 |
Why?
|
| Sensitivity and Specificity | 5 | 2019 | 4971 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 487 | 0.120 |
Why?
|
| Air | 1 | 2014 | 63 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2018 | 592 | 0.120 |
Why?
|
| Fracture Fixation, Internal | 1 | 2015 | 76 | 0.120 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 295 | 0.120 |
Why?
|
| Cognition Disorders | 1 | 2020 | 786 | 0.120 |
Why?
|
| Homicide | 1 | 2014 | 36 | 0.120 |
Why?
|
| Iridium Radioisotopes | 1 | 2013 | 56 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2017 | 549 | 0.120 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 334 | 0.120 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 4314 | 0.120 |
Why?
|
| Crime Victims | 1 | 2014 | 59 | 0.120 |
Why?
|
| Hypertension | 1 | 2023 | 1503 | 0.110 |
Why?
|
| Planning Techniques | 1 | 2013 | 15 | 0.110 |
Why?
|
| Sarcoma | 2 | 2022 | 1725 | 0.110 |
Why?
|
| Age of Onset | 3 | 2021 | 827 | 0.110 |
Why?
|
| Thyroid Neoplasms | 1 | 2024 | 1866 | 0.110 |
Why?
|
| Regression Analysis | 1 | 2016 | 1546 | 0.110 |
Why?
|
| Survival Rate | 7 | 2019 | 12221 | 0.110 |
Why?
|
| Spinal Cord | 2 | 2016 | 690 | 0.110 |
Why?
|
| Time Factors | 7 | 2021 | 12926 | 0.110 |
Why?
|
| Software Validation | 1 | 2012 | 32 | 0.110 |
Why?
|
| Vascular Diseases | 1 | 2015 | 246 | 0.110 |
Why?
|
| Exercise | 1 | 2020 | 1183 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4892 | 0.110 |
Why?
|
| Laryngostenosis | 1 | 2012 | 37 | 0.100 |
Why?
|
| Film Dosimetry | 1 | 2012 | 59 | 0.100 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 1143 | 0.100 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 361 | 0.100 |
Why?
|
| Equipment Failure Analysis | 3 | 2011 | 329 | 0.100 |
Why?
|
| Protons | 2 | 2013 | 473 | 0.100 |
Why?
|
| Pain | 1 | 2020 | 1658 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 5319 | 0.100 |
Why?
|
| Electrical Equipment and Supplies | 1 | 2011 | 9 | 0.100 |
Why?
|
| Parotid Gland | 1 | 2011 | 112 | 0.100 |
Why?
|
| Cancer Care Facilities | 1 | 2015 | 884 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2020 | 1330 | 0.100 |
Why?
|
| Barrett Esophagus | 1 | 2016 | 569 | 0.090 |
Why?
|
| Prognosis | 6 | 2020 | 21713 | 0.090 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 799 | 0.090 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 2576 | 0.090 |
Why?
|
| Curriculum | 1 | 2016 | 860 | 0.090 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 29902 | 0.090 |
Why?
|
| Indium | 1 | 2009 | 20 | 0.090 |
Why?
|
| Equipment Failure | 1 | 2011 | 191 | 0.090 |
Why?
|
| Parotid Neoplasms | 1 | 2011 | 148 | 0.090 |
Why?
|
| Catheterization | 1 | 2012 | 410 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 4549 | 0.090 |
Why?
|
| Radiation Monitoring | 1 | 2009 | 49 | 0.090 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2017 | 1823 | 0.090 |
Why?
|
| Luteinizing Hormone | 2 | 2019 | 165 | 0.090 |
Why?
|
| Educational Status | 2 | 2021 | 397 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2020 | 6100 | 0.090 |
Why?
|
| Cardiotoxicity | 2 | 2020 | 155 | 0.090 |
Why?
|
| Tissue Distribution | 2 | 2013 | 875 | 0.090 |
Why?
|
| Organ Size | 1 | 2010 | 690 | 0.080 |
Why?
|
| Research Design | 1 | 2016 | 1544 | 0.080 |
Why?
|
| Obesity | 2 | 2023 | 2884 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2016 | 2203 | 0.080 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 3168 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2010 | 2027 | 0.080 |
Why?
|
| Gold | 1 | 2009 | 270 | 0.080 |
Why?
|
| Stomach | 1 | 2010 | 387 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 945 | 0.080 |
Why?
|
| Surgical Procedures, Operative | 1 | 2011 | 383 | 0.080 |
Why?
|
| Brachytherapy | 1 | 2013 | 977 | 0.070 |
Why?
|
| SEER Program | 2 | 2021 | 1000 | 0.070 |
Why?
|
| Whole Genome Sequencing | 2 | 2019 | 338 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 13658 | 0.070 |
Why?
|
| Cause of Death | 2 | 2021 | 752 | 0.070 |
Why?
|
| Quality Control | 2 | 2019 | 457 | 0.070 |
Why?
|
| Mammography | 2 | 2022 | 1010 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2016 | 1375 | 0.060 |
Why?
|
| Cognition | 2 | 2021 | 968 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 7702 | 0.060 |
Why?
|
| Linear Energy Transfer | 1 | 2005 | 98 | 0.060 |
Why?
|
| Switzerland | 1 | 2023 | 21 | 0.060 |
Why?
|
| Podophyllotoxin | 1 | 2023 | 63 | 0.060 |
Why?
|
| Liver Neoplasms | 2 | 2010 | 4557 | 0.060 |
Why?
|
| Skin | 2 | 2019 | 1259 | 0.060 |
Why?
|
| Employment | 1 | 2024 | 129 | 0.060 |
Why?
|
| Germ-Line Mutation | 2 | 2018 | 1046 | 0.060 |
Why?
|
| Loneliness | 1 | 2023 | 27 | 0.060 |
Why?
|
| Pericardium | 2 | 2015 | 157 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 4849 | 0.050 |
Why?
|
| Daunorubicin | 1 | 2023 | 301 | 0.050 |
Why?
|
| Mass Screening | 2 | 2022 | 1509 | 0.050 |
Why?
|
| Brain | 1 | 2015 | 4113 | 0.050 |
Why?
|
| Equipment Design | 3 | 2011 | 1204 | 0.050 |
Why?
|
| Radiopharmaceuticals | 3 | 2019 | 1301 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2023 | 295 | 0.050 |
Why?
|
| Credentialing | 1 | 2021 | 63 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2019 | 1226 | 0.050 |
Why?
|
| Unemployment | 1 | 2021 | 31 | 0.050 |
Why?
|
| Marital Status | 1 | 2021 | 98 | 0.050 |
Why?
|
| Sleep | 1 | 2024 | 413 | 0.050 |
Why?
|
| Probability | 2 | 2013 | 866 | 0.050 |
Why?
|
| Role | 1 | 2020 | 48 | 0.050 |
Why?
|
| Machine Learning | 1 | 2023 | 319 | 0.050 |
Why?
|
| Animals | 3 | 2020 | 59536 | 0.050 |
Why?
|
| Speech | 1 | 2021 | 133 | 0.050 |
Why?
|
| Chemoradiotherapy | 2 | 2019 | 1946 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2022 | 434 | 0.050 |
Why?
|
| Remote Sensing Technology | 1 | 2019 | 12 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 2594 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2020 | 173 | 0.050 |
Why?
|
| Luminescence | 1 | 2019 | 44 | 0.040 |
Why?
|
| Puberty, Precocious | 1 | 2019 | 29 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2021 | 248 | 0.040 |
Why?
|
| Human Growth Hormone | 1 | 2019 | 82 | 0.040 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2019 | 156 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2021 | 756 | 0.040 |
Why?
|
| Lower Extremity | 1 | 2022 | 299 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 202 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 556 | 0.040 |
Why?
|
| Lumbar Vertebrae | 1 | 2020 | 245 | 0.040 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2019 | 241 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2021 | 32848 | 0.040 |
Why?
|
| Mice | 1 | 2020 | 34495 | 0.040 |
Why?
|
| Office Visits | 1 | 2019 | 97 | 0.040 |
Why?
|
| Exercise Test | 1 | 2019 | 312 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 2019 | 401 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2021 | 624 | 0.040 |
Why?
|
| Growth Disorders | 1 | 2019 | 218 | 0.040 |
Why?
|
| Purkinje Cells | 1 | 2019 | 143 | 0.040 |
Why?
|
| Drug Therapy | 1 | 2019 | 205 | 0.040 |
Why?
|
| Lung Injury | 1 | 2019 | 131 | 0.040 |
Why?
|
| Sweden | 1 | 2017 | 70 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2019 | 460 | 0.040 |
Why?
|
| Validation Studies as Topic | 1 | 2017 | 43 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2021 | 390 | 0.040 |
Why?
|
| Gonadal Hormones | 1 | 2017 | 4 | 0.040 |
Why?
|
| Seizures | 1 | 2023 | 989 | 0.040 |
Why?
|
| raf Kinases | 1 | 2017 | 81 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 15862 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2019 | 263 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 383 | 0.040 |
Why?
|
| End Stage Liver Disease | 1 | 2019 | 170 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 595 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 1183 | 0.040 |
Why?
|
| Lung | 2 | 2020 | 3151 | 0.040 |
Why?
|
| Mental Health | 1 | 2020 | 415 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 388 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 978 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2019 | 481 | 0.040 |
Why?
|
| Family | 1 | 2020 | 736 | 0.040 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 1618 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 5047 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2023 | 3005 | 0.030 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2016 | 33 | 0.030 |
Why?
|
| Reference Standards | 1 | 2017 | 339 | 0.030 |
Why?
|
| Haplotypes | 1 | 2018 | 856 | 0.030 |
Why?
|
| Bone Marrow Transplantation | 1 | 2021 | 1581 | 0.030 |
Why?
|
| Cerebellum | 1 | 2019 | 449 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 2019 | 1178 | 0.030 |
Why?
|
| Carbon | 1 | 2016 | 149 | 0.030 |
Why?
|
| Lung Transplantation | 1 | 2019 | 359 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2018 | 627 | 0.030 |
Why?
|
| Medical Errors | 1 | 2017 | 219 | 0.030 |
Why?
|
| Echocardiography | 1 | 2020 | 1182 | 0.030 |
Why?
|
| Testosterone | 1 | 2019 | 619 | 0.030 |
Why?
|
| Ovary | 1 | 2018 | 668 | 0.030 |
Why?
|
| Cobalt Radioisotopes | 1 | 2013 | 42 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 186 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 573 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2014 | 187 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 2316 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 755 | 0.030 |
Why?
|
| Swine | 1 | 2017 | 1541 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 2015 | 196 | 0.030 |
Why?
|
| Lymphatic Irradiation | 1 | 2013 | 133 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 1085 | 0.030 |
Why?
|
| Anxiety | 1 | 2020 | 1179 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 701 | 0.030 |
Why?
|
| Optics and Photonics | 1 | 2013 | 146 | 0.030 |
Why?
|
| Disease Progression | 1 | 2023 | 6682 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2019 | 908 | 0.030 |
Why?
|
| Radiographic Image Enhancement | 1 | 2015 | 402 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2012 | 111 | 0.030 |
Why?
|
| Mediastinum | 1 | 2013 | 268 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 4298 | 0.030 |
Why?
|
| Parotid Diseases | 1 | 2011 | 12 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 649 | 0.020 |
Why?
|
| Radiography | 1 | 2016 | 1904 | 0.020 |
Why?
|
| Psychometrics | 1 | 2016 | 937 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 4938 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 960 | 0.020 |
Why?
|
| Retreatment | 1 | 2012 | 452 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2013 | 183 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2019 | 1112 | 0.020 |
Why?
|
| Laryngoscopy | 1 | 2012 | 183 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2018 | 2086 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 2403 | 0.020 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2011 | 137 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 2170 | 0.020 |
Why?
|
| Airway Obstruction | 1 | 2012 | 261 | 0.020 |
Why?
|
| Surface Properties | 1 | 2009 | 180 | 0.020 |
Why?
|
| Leukemia | 1 | 2017 | 1635 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 6942 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 8865 | 0.020 |
Why?
|
| Smoking | 1 | 2017 | 2440 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2011 | 690 | 0.020 |
Why?
|
| Mastectomy, Segmental | 1 | 2013 | 1026 | 0.020 |
Why?
|
| Myocardium | 1 | 2013 | 1313 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 3552 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 2012 | 1202 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 3719 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 4744 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 10035 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2011 | 2967 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 7548 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2012 | 2341 | 0.010 |
Why?
|